未登录

F

François Mercier

roche innovation center basel

H指数:33

被引数:3,631

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and Recommendations

在肿瘤药物开发中构建混合药代动力学-机器学习模型：现状与建议

CPT: Pharmacometrics & Systems Pharmacology

IF0

2025-10-170

OAAI

Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-07-123

OAAI

Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm (vol 26, 53, 2024)

IF3.7

2024-06-060

OA

Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm

IF3.7

2024-04-231

PRE

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-04-172

OAAI

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION

IF7.5

2023-03-0126

OAAI

Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models

BRITISH JOURNAL OF CANCER

IF6.8

2023-02-1011

OA

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-01-299

OAAI

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

IF10.2

2023-01-0311

OA

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment

IF5.7

2023-01-0110

OAAI

Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-02-0313

OA

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy

IF8.3

2022-02-0111

OAAI

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

INVESTIGATIONAL NEW DRUGS

IF2.7

2021-08-2113

OAAI

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors

INVESTIGATIONAL NEW DRUGS

IF2.7

2021-01-1824

OAAI

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-12-0754

OAAI

Opportunities for Quantitative Translational Modeling in Oncology

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-07-258

OAAI

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-07-0537

PREAI

HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

VALUE IN HEALTH

IF6

2018-10-010

OAAI

Leveraging tumor size and time to death from bevacizumab (BEV) historical data to predict overall survival in ovarian cancer patients treated with vanucizumab (VAN)

CANCER RESEARCH

IF16.6

2018-07-012

PRE

COST COMPARISON OF ORAL VERSUS IV VINORLBINE IN FRANCE IN ADVANCED BREAST CANCER

VALUE IN HEALTH

IF6

2015-11-010

OAAI